In brief: CSL, Progen Industries, Mayne Group
Tuesday, 28 June, 2005
CSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12. "Combined with the buyback completed in May of this year it is likely that we will have returned to shareholders in excess of the AUD$550 million we raised to acquire the global plasma therapeutics business of Aventis Behring in December 2004. At the same time the market value for CSL has more than doubled since making the announcement to acquire the business," said CSL managing director Brian McNamee in a statement.
Progen Industries (ASX:PGL; NASDAQ:PGLAF) has engaged San Francisco-based global life sciences merchant bank Burrill & Company to accelerate a partnering transaction for the company's lead anti-cancer product PI-88. Progen's vice president business development Darren Schliebs has resigned.
Mayne Group (ASX:MAY) has appointed Nora Scheinkestel as a non-executive director effective July 1.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
